{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:35:13Z","timestamp":1792100113584,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,7,14]],"date-time":"2017-07-14T00:00:00Z","timestamp":1499990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,7,14]],"date-time":"2017-07-14T00:00:00Z","timestamp":1499990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/bcj.2017.62","type":"journal-article","created":{"date-parts":[[2017,7,14]],"date-time":"2017-07-14T13:20:26Z","timestamp":1500038426000},"page":"e583-e583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia"],"prefix":"10.1038","volume":"7","author":[{"given":"Z","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L J","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J E","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J D","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H M","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,14]]},"reference":[{"key":"BFbcj201762_CR1","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.leukres.2007.08.017","volume":"32","author":"T Burmeister","year":"2008","unstructured":"Burmeister T, Reinhardt R . A multiplex PCR for improved detection of typical and atypical BCR\u2013ABL fusion transcripts. Leuk Res 2008; 32: 579\u2013585.","journal-title":"Leuk Res"},{"key":"BFbcj201762_CR2","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","volume":"127","author":"P Jain","year":"2016","unstructured":"Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Shamanna RK et al. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 2016; 127: 1269\u20131275.","journal-title":"Blood"},{"key":"BFbcj201762_CR3","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/S0959-8049(00)00128-3","volume":"36","author":"RA Perego","year":"2000","unstructured":"Perego RA, Costantini M, Cornacchini G, Gargantini L, Bianchi C, Pungolino E et al. The possible influences of B2A2 and B3A2 BCR\/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer 2000; 36: 1395\u20131401.","journal-title":"Eur J Cancer"},{"key":"BFbcj201762_CR4","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","volume":"99","author":"B Hanfstein","year":"2014","unstructured":"Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C et al. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica 2014; 99: 1441\u20131447.","journal-title":"Haematologica"},{"key":"BFbcj201762_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00277-002-0433-z","volume":"81","author":"M Hur","year":"2002","unstructured":"Hur M, Song E, Kang S-H, Shin D-H, Kim J, Park S et al. Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia. Ann Hematol 2002; 81: 219\u2013223.","journal-title":"Ann Hematol"},{"key":"BFbcj201762_CR6","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2169\/internalmedicine.41.1183","volume":"41","author":"A Ohsaka","year":"2002","unstructured":"Ohsaka A, Shiina S, Kobayashi M, Kudo H, Kawaguchi R . Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCR-ABL). Intern Med 2002; 41: 1183\u20131187.","journal-title":"Intern Med"},{"key":"BFbcj201762_CR7","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.2169\/internalmedicine.41.1092","volume":"41","author":"S Ohtake","year":"2002","unstructured":"Ohtake S . Chronic myelogenous leukemia with p190BCR-ABL expression: the missing link with monocytosis. Intern Med 2002; 41: 1092\u20131093.","journal-title":"Intern Med"},{"key":"BFbcj201762_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/ijlh.12616","volume":"39","author":"AK Arun","year":"2016","unstructured":"Arun AK, Senthamizhselvi A, Mani S, Vinodhini K, Janet NB, Lakshmi KM et al. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients. Int J Lab Hematol 2016; 39: 235\u2013242.","journal-title":"Int J Lab Hematol"},{"key":"BFbcj201762_CR9","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1182\/blood.V124.21.5528.5528","volume":"124","author":"G Catania","year":"2014","unstructured":"Catania G, Monaco F, Pini M, Corsetti MT, Salvio M, Trincheri N et al. Prognostic impact of p190 and p210 co-expression at diagnosis in chronic myeloid leukemia (CML) patients treated with Imatinib. Blood 2014; 124: 5528.","journal-title":"Blood"},{"key":"BFbcj201762_CR10","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391\u20132405.","journal-title":"Blood"},{"key":"BFbcj201762_CR11","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","volume":"119","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012; 119: 1981\u20131987.","journal-title":"Blood"},{"key":"BFbcj201762_CR12","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","volume":"127","author":"W Wang","year":"2016","unstructured":"Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood 2016; 127: 2742\u20132750.","journal-title":"Blood"},{"key":"BFbcj201762_CR13","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1002\/cncr.26147","volume":"117","author":"A Quint\u00e1s\u2010Cardama","year":"2011","unstructured":"Quint\u00e1s\u2010Cardama A, Kantarjian H, Shan J, Jabbour E, Abruzzo LV, Verstovsek S et al. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer 2011; 117: 5085\u20135093.","journal-title":"Cancer"},{"key":"BFbcj201762_CR14","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1200\/JCO.2009.26.7963","volume":"28","author":"F Castagnetti","year":"2010","unstructured":"Castagnetti F, Testoni N, Luatti S, Marzocchi G, Mancini M, Kerim S et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with Imatinib mesylate: GIMEMA CML Working Party Analysis. J Clin Oncol 2010; 28: 2748\u20132754.","journal-title":"J Clin Oncol"},{"key":"BFbcj201762_CR15","doi-asserted-by":"publisher","first-page":"e490","DOI":"10.1038\/bcj.2016.96","volume":"6","author":"W Wang","year":"2016","unstructured":"Wang W, Chen Z, Hu Z, Yin C, Li S, Bai S et al. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia. Blood Cancer J 2016; 6: e490.","journal-title":"Blood Cancer J"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201762.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201762","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bcj.2017.62","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201762.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T17:28:31Z","timestamp":1671730111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,14]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7]]}},"alternative-id":["BFbcj201762"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2017.62","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,14]]},"assertion":[{"value":"14 July 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}